Brief: AnGes says joint development with Vasomune Therapeutics
30/07/2018 07:53
July 30(Reuters) - AnGes Inc 4563.T
* Says it signed contract for joint development of drugs
used for
acute respiratory insufficiency, with Canada biotechnology firm
Vasomune Therapeutics Inc
Source text in Japanese:https://goo.gl/zrB7Xz
Further company coverage: 4563.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001